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Abstract (250 words) 
 
Background: The prophylactic benefit of statins in reducing the incidence of 
contrast-induced acute kidney injury (CI-AKI) has been investigated in several studies 
with conflicting results. We sought to investigate whether statin pretreatment prevents 
CI-AKI in coronary artery disease (CAD) patients undergoing percutaneous coronary 
intervention (PCI). 
Methods: A total of 2198 CAD patients who underwent PCI, except for those 
undergoing dialysis or who died within 7 days after angioplasty, were analyzed from the 
ICAS (Ibaraki Cardiovascular Assessment Study) multicenter registry. Analyzed 
subjects were divided into 2 groups according to statin pretreatment: statin pretreatment 
(n=839) and non-statin pretreatment (n=1359). Selection bias of statin pretreatment was 
adjusted by propensity score-matching method: pretreatment statin (n=565) and non- 
statin pretreatment (n=565). CI-AKI was defined as an increase in serum creatinine of ≥ 
25% or 0.5 mg/dl from baseline within 1 week of contrast medium exposure.  
Results: A total of 192 (8.7%) patients developed CI-AKI. No significant differences 
were observed in baseline patient characteristics between the statin and non-statin 
pretreatment groups after propensity score matching. In the propensity score-matched 
groups, the incidence of CI-AKI was significantly lower in patients with statin 
pretreatment than in those without statin pretreatment (3.5% vs.10.6%, odds ratio [OR]: 
0.31, 95% confidence interval [CI]: 0.18-0.52, P<0.001). Multivariate logistic 
regression analysis showed that statin pretreatment remained an independent negative 
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predictor of CI-AKI (OR: 0.31, 95%CI: 0.18-0.53, P<0.001) among propensity 
score-matched subjects. 
Conclusions: Statin pretreatment was associated with significant decrease in the risk of 
CI-AKI in CAD patients undergoing PCI in the ICAS registry. 
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1. Introduction 
Contrast-induced acute kidney injury (CI-AKI), an important complication that can 
occur after percutaneous coronary intervention (PCI) [1-3], has been associated with 
both short- and long-term adverse outcomes, including the need for renal replacement 
therapy, major cardiac adverse events, and mortality [4]. Previous reports showed that 
approximately 10% of patients develop CI-AKI following PCI [4]. Several prophylactic 
strategies, including periprocedural hydration with normal saline, limiting the amount of 
contrast medium, and using iso- or low-osmolar contrast are well established measures 
for the prevention of CI-AKI [2,3,5-7]. 
Statins are a class of drug that improves the lipid profile of patients and has been 
reported to have pleiotropic effects in the vasculature. A few studies focusing on statin 
treatment as a specific prophylactic agent against CI-AKI have been published with 
conflicting results [8-12]. Moreover, the supposed pleiotropic effects of preventing 
post-procedural AKI represent a wide-spread range of effects that they have been 
reported in aortic valve surgery as well, not only in coronary artery disease (CAD) 
patients [13]. The aim of this study was to investigate whether statin pretreatment 
prevents CI-AKI in CAD patients undergoing PCI. To address this issue, we analyzed 
consecutive CAD patients undergoing PCI who were enrolled in the Ibaraki 
Cardiovascular Assessment Study (ICAS) registry. 
 
2. Methods 
2.1. Study Design 
The ICAS registry was designed as a retrospective multicenter observational study 
of CAD in Ibaraki prefecture in Japan. All consecutive CAD patients who underwent 
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PCI at 12 cooperating centers were enrolled in this registry. Study subjects are 
summarized in Figure 1. A total of 2657 patients were enrolled from April 2007 to April 
2010. We excluded the patients on dialysis (n=83) and those who died within 7- days of 
PCI (n=56). Patients with no information regarding serial measurements of serum 
creatinine were also excluded (n=320). The study population thus comprised 2198 
patients who were divided into 2 groups according to statin pretreatment: statin 
pretreatment group (n=839) and non-pretreatment group (n=1359). This study was 
approved by the institutional review boards or ethics committees of all participating 
institutions. 
 
2.2. Clinical Data Collection 
Patient demographic information, cardiovascular risk factors, laboratory findings, 
angiographic findings, and percutaneous procedural characteristics were recorded 
according to information on medical charts at initial enrollment in the registry. Oral 
medications prescribed before the PCI procedure were also assessed. Statin pretreatment 
was defined as taking a statin prior to contrast exposure. The serum concentration of 
creatinine was measured serially, before contrast exposure and at 24-, 48-, and 72- hour 
after PCI. When it was not available at 48- or 72- hour post PCI, we used data obtained 
within 1 week after contrast exposure. Estimated glomerular filtration rate (GFR) was 
calculated with the Modification of Diet in Renal Disease study equation modified for 
the Japanese population [14] and estimated GFR of <60ml/min/1.73m2 was defined as 
chronic kidney disease. Contrast volume (CV) used during each PCI was collected, and 
the CV/GFR ratio was calculated by dividing CV by the baseline estimated GFR. The 
Mehran risk score was calculated on the basis of information collected before the 
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procedure. Briefly, this is a scoring system based on comorbidities and procedural risk 
factors, including hypotension, intra-aortic balloon pump use, heart failure, age >75 
years, anemia, diabetes mellitus, volume of contrast, and renal function. Predicted 
incidences of CI-AKI are reported to be 7.5%, 14%, 26.1%, and 57.3% for scores of ≤5 
(low risk), 6-10 (moderate risk), 11-15 (high risk), and ≥16 (very high risk), respectively 
[15]. Based on the baseline diagnostic angiogram, SYNTAX score was calculated using 
the algorithm which is available on the SYNTAX website [16]. 
 
2.3. Follow-up Survey and Study Endpoint 
All follow-up data and clinical events were surveyed once a year during the study 
period. Data for patients who were lost to follow-up were censored at the time of the 
last contact. The primary endpoint for the present analysis was the development of 
CI-AKI defined as an increase in serum creatinine of ≥25% or 0.5 mg/dl from the 
baseline within 1 week after contrast exposure [6]. The serum creatinine concentration 
was not available at 48- or 72- hour in 25% of the patients; therefore, we used the data 
obtained within 1 week after contrast exposure. Secondary endpoints assessed included 
the composite and individual endpoint of requiring dialysis and/or all-cause death 
within 30, 180, and 360 days. All deaths were confirmed by medical charts or by 
contacting the referring physician and/or patient’s family, and all events were registered 
by the attending physicians. 
 
2.4. Statistical Analysis 
Continuous variables are reported as mean ± SD or median and interquartile ranges, 
as appropriate. The Student t-test and nonparametric Mann-Whitney test were used to 
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determine differences between mean values for parametrically and non-parametrically 
distributed variables, respectively. Categorical variables are reported as absolute values 
and percentages and were analyzed by either chi-square or Fisher exact test, as 
appropriate. Stratified analysis based on Mehran risk score was performed with the 
Breslow-Day test of homogeneity and Cochran-Mantel-Haenszel test. Kaplan-Meier 
curves were constructed to assess event-free survival rates, and the log-rank test was 
used to identify significant differences in unadjusted survival rate among each groups. 
Because use of a statin was decided by individual physicians, a propensity score was 
calculated to adjust for potential selection bias of statin pretreatment. For each patient, a 
propensity score indicating the probability of being on a pretreatment statin was 
calculated by binary logistic regression analysis with forced simultaneous entry method. 
We included 24 covariates to calculate propensity score: demographic data such as age, 
male sex; baseline characteristics such as hypertension, diabetes, current smoking, 
estimated GFR, body mass index, family history of cardiovascular disease, prior history 
of myocardial infarction, PCI, bypass grafting, heart failure, stroke, and peripheral 
artery disease; other risk factors such as ejection fraction, syntax score, culprit lesion in 
the left anterior descending artery, and emergency procedure; and concomitant 
medications of aspirin, clopidogrel, beta-blocker, angiotensin converting enzyme 
inhibitor and/or angiotensin II receptor blocker, calcium channel blocker, and nitrate. 
Goodness of fit of the propensity score was evaluated by the Hosmer-Lemeshow test 
and the c statistic. The propensity score was used in the following two ways. First, the 
derived propensity scores were used to match 565 statin pretreatment patients with 
non-pretreatment patients at a 1:1 ratio (Figure 1). The maximum difference in the 
propensity score allowed for a match was 0.015 [17]. Second, propensity scores were 
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used for adjustment for multivariate analysis [17]. Multivariate logistic analysis was 
performed to determine the independent effect of statin pretreatment for the primary 
endpoint with stepwise backward elimination method according to a selection-stay 
criterion of P <0.05. Covariates included age, male sex, statin pretreatment, acute 
coronary syndrome, ejection fraction ≤45%, multivessel disease, and Mehran risk score. 
When all subjects were analyzed, propensity scores were also incorporated into a 
subsequent multivariate model [17]. A two-sided P value of <0.05 was considered to be 
statistically significant throughout the analysis. Data were analyzed with IBM SPSS 
Statistics 18.0 for Windows (SPSS Inc., Chicago, IL). 
 
3. Results 
3.1. Baseline Patient Characteristics and Statin Use 
We analyzed a total of 2198 consecutive CAD patients who underwent PCI in this 
study. Mean age was 69.5±10.7 years and 77% of patients were men. Before undergoing 
PCI, the prescription rate of statin was 38% among all patients. Of these, 82% of 
patients had been taking a statin ≥4 weeks before contrast exposure. The statins used 
were included; rosuvastatin 329, atorvastatin 172, pitavastatin 97, pravastatin 79, 
simvastatin 22, fluvastatin 16, and unknown 124. The propensity score derivation model 
was reliable (Hosmer-Lemeshow test, χ2=4.99, p=0.76) and discriminative (c statistic, 
0.80). Baseline characteristics of all patients and propensity score-matched patients are 
listed in Table 1. After propensity score matching, well-balanced distribution of the 
covariates was confirmed between with and without statin pretreatment groups. 
 
3.2. Laboratory Data, Contrast Medium, and Mehran Risk Score 
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Laboratory data, contrast volume, and Mehran risk score are shown in Table 2. The 
concentrations of total cholesterol and LDL cholesterol remained significantly different 
between the 2 groups even after propensity score matching. There were no significant 
differences in the CV/GFR ratio between the 2 groups. All procedures were performed 
with use of low-osmolar contrast medium. There was a significant difference in Mehran 
risk score between the 2 groups; however, this difference disappeared after propensity 
score matching. 
 
3.3. Primary and Secondary Endpoints 
Of the 2198 patients, 192 (8.7%) patients developed CI-AKI following PCI. In all 
patients, the incidence of CI-AKI was observed less frequently in those with statin 
pretreatment than in those without statin pretreatment (3.9% vs. 11.7%, respectively, 
odds ratio [OR]: 0.31, 95% confidence interval [CI]: 0.21-0.45, P<0.001). Even after 
propensity score matching, similar benefit was confirmed in patients with statin 
pretreatment (OR: 0.31, 95% CI: 0.18-0.52, P<0.001) (Table 3). When the patients were 
divided into 4 groups according to Mehran risk score, the incidence of CI-AKI rose 
gradually with the increase in Mehran risk score (Figure 2 A, B). The preventive benefit 
of statin pretreatment was observed in patients with Mehran risk score of ≤5, 6 to 10, 
and 11 to 15. The number of subjects in the very high risk group with Mehran risk score 
of ≥16 was small, and statin pretreatment did not show the preventing effect for CI-AKI 
in this group. Overall, the homogeneity of the effect of statin pretreatment were 
indicated when comparing them across Mehran risk score strata (χ2 = 6.37, P for 
interaction = 0.095). The significant association between statin pretreatment and 
CI-AKI was observed for all patients while controlling for the Mehran risk score (χ2 = 
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33.43, P<0.001). Moreover, the serum creatinine concentration was not available at 48- 
or 72- hour in 25% of the patients; therefore, we used the data obtained within 1 week 
after contrast exposure. We observed a similar relation in CI-AKI development between 
patients who had 48- or 72- hour and 1 week measurement of serum creatinine (OR: 
0.39, 95% CI: 0.19-0.82 vs. OR: 0.33, 95% CI 0.21-0.52, respectively, P for interaction 
= 0.65). 
Multivariate logistic regression analysis for primary endpoint showed that statin 
pretreatment was an independent predictor of the development of CI-AKI following PCI 
among all subjects after adjusting for propensity score (OR: 0.62, 95% CI: 0.40-0.97, 
P=0.036) (Table 4). Similar benefit was also confirmed among propensity 
score-matched subjects (OR: 0.31, 95% CI: 0.18-0.53, P<0.001) (Table 4). 
The secondary composite endpoint of death or requiring dialysis within either 30, 
180, and 360 days was significantly lower in patients with statin pretreatment than those 
in without statin pretreatment (within 30 days: 0.1% vs. 1.3%, P=0.002; within 180 
days: 1.2% vs. 3.4%, P=0.002; within 360 days: 1.8% vs. 4.6%, P<0.001 for with 
versus without statin pretreatment, respectively), which was mainly attributed to the 
difference of mortality (Table 3). After propensity score matching, however, there were 
no significant differences in secondary endpoint between the 2 groups (Table 3). 
Because receiver-operating characteristics analysis derived the cut-off value of Mehran 
risk score was 7, with a sensitivity of 74% and a specificity of 62% for predicting 
composite secondary endpoint, the subjects were recategorized according to the cut-off 
value of Mehran risk score (≤7 or >7) and statin pretreatment. Kaplan-Meier curves 
showed that the patients with Mehran risk score of >7 and who did not receive statin 
pretreatment had worst clinical prognosis among all subjects (Figure 3A) and propensity 
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score-matched subjects (Figure 3B). 
 
4. Discussion 
In the present study, we evaluated the role of statin pretreatment for prevention of 
CI-AKI among consecutive patients undergoing PCI. The present study comprised an 
observational cohort of consecutive CAD patients who were treated with PCI, and the 
major findings of the study are as follows. First, the incidence of CI-AKI was 8.7% 
overall in consecutive and unselective patients who underwent PCI. The significant 
decrease in CI-AKI development following PCI was shown in patients with statin 
pretreatment after propensity score matching (OR: 0.31, 95% CI: 0.18-0.52, P<0.001). 
The patients with Mehran risk score of ≤15 had substantial benefit for preventing 
CI-AKI, and statin pretreatment was a negative independent predictor for CI-AKI after 
adjusting for propensity score. Second, clinical outcomes including death and requiring 
dialysis within 30, 180, and 360 days following PCI were not significantly different 
between patients with and without statin pretreatment among propensity score-matched 
subjects. 
The incidence of CI-AKI has been an important potential concern because of its effect 
on morbidity and mortality [4]. Although the pathogenesis of CI-AKI is not well known, 
it has been hypothesized to be due to oxidative stress, reduction in renal blood flow, 
tubular obstruction, and direct toxicity to tubular epithelium [1,4,18]. Statins are mainly 
used as lipid-lowering agents and are also known to have pleiotropic effects, including 
increased nitric oxide production, antioxidant effects, and anti-inflammatory properties 
[19,20]. The rational for the use of statins for the prevention of CI-AKI relates to its 
pleiotropic effects, leading to reduction of renal oxidative stress and enhancement of 
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renal nitric oxide. Recently, Quintavalle et al. showed that pretreatment with 
atrovastatin prevents contrast-induced renal cell apoptosis by reducing reactive oxygen 
species production in vitro model [21]. 
There is general agreement that chronic kidney disease is the most crucial risk factor for 
CI-AKI, and CV is also a main procedure-related risk factor for CI-AKI [2,4,22]. The 
CV/GFR ratio has recently been reported to be a useful tool for predicting the 
development of CI-AKI, as well as the need for renal replacement therapy [6,23]. The 
other important risk factors for CI-AKI include age over 70 years, diabetes, congestive 
heart failure, dehydration, and concurrent administration of nephrotoxic agents, i.e., 
non-steroid anti-inflammatory drugs [2,4,22,24]. The mechanism and risk of CI-AKI are 
multifactorial, and therefore, identification of patients at high risk for the development 
of CI-AKI is of major importance. The Mehran risk score, based on comorbidities and 
procedural risk factors, is a scoring system that is useful for predicting the development 
of CI-AKI in patients undergoing non-emergent and emergent PCI [15,25]. In this study, 
we opted to perform risk stratification by using the Mehran risk score, which makes our 
study relevant and unique. Although the patients with a Mehran risk score of ≥16 had a 
very high incidence of CI-AKI and showed no significant effects of statin pretreatment, 
statin pretreatment provided substantial benefit of CI-AKI prevention in the patients 
with Mehran risk score of ≤15 in our study. Multivariate logistic analysis showed that 
statin pretreatment was a negative independent predictor of CI-AKI development even 
after adjustment or matching for propensity score. 
The prophylactic benefit of statin for reduction of CI-AKI incidence has been 
investigated in several studies with conflicting results [8-12]. Patti et al. reported that 
the patients with a statin had a significantly lower incidence of CI-AKI than those 
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without a statin among 434 patients undergoing non-emergent PCI (incidence of 
CI-AKI was 3% with vs. 27% without statin, P<0.0001) [8]. Similarly, the benefit of 
statins in the prevention of CI-AKI was reported by Khanal et al. based on a large 
database of 29409 patients undergoing emergent and non-emergent PCI (incidence of 
CI-AKI was 4.4% with vs. 5.9% without statin, P<0.0001) [9]. However, Kandula et al. 
showed that statins were not associated with prevention of CI-AKI when adjusted for 
the propensity of receiving statins (OR: 1.6, 95% CI: 0.86-3.22, P=0.12) [10]. Although 
observational studies, such as those listed above, often have treatment bias for statin 
prescription, a few randomized controlled studies exist that address this topic. The 
PROMISS trial, which randomly allocated 274 patients with renal insufficiency to 
simvastatin 40 mg or placebo, showed no benefit for prevention of CI-AKI [11]. 
Recently, Patti et al. conducted the ARMYDA- CI-AKI randomized control trial, which 
showed that pretreatment with high-dose atorvastatin at 80 mg was effective in 
preventing CI-AKI in patients with acute coronary syndrome undergoing PCI (OR: 0.34, 
95% CI: 0.12-0.97, P=0.043) [12]. 
The incidence of CI-AKI is associated with poor long-term clinical outcomes, but few 
studies of statin pretreatment have addressed long-term prognosis, such as requiring 
dialysis, morbidity, and mortality [18]. In our study, despite the significant decrease of 
CI-AKI with statin pretreatment, there were no significant differences in mortality 
and/or renal dysfunction requiring dialysis within 30, 180, and 360 days after propensity 
score matching. The considerable reason might be due to the current widespread use of 
statins for CAD patients after PCI. The effects of improving long-term clinical 
outcomes, such as mortality, as well as preventing CI-AKI, should be confirmed by 
well-designed, randomized controlled trial. 
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5. Study Limitations 
Several limitations in the design of the ICAS registry should be mentioned. First, this 
study was based on a non-randomized observational retrospective design. The choice of 
statin was not allocated randomly but was decided by direction of the individual 
physician. Therefore, this might have introduced potential biases related to unmeasured 
or hidden covariates in selection of prescribed medications and leading to potential 
incomplete and/or inexact matching, even though multiple variables were adjusted by 
propensity score-matched and -adjusted analysis. Our study thus is inferior in 
comparative validity compared with a randomized, controlled trial. Moreover, because 
this study was an observational design, there were differences in the study subjects 
between with and without statin pretreatment on many of the measured covariates. We 
controlled for these between-group differences using propensity score-matching in order 
to attenuate the impact of treatment selection bias when estimating causal treatment 
effects. Propensity score-matching commonly entails creating pairs of treated and 
untreated subjects who have similar values of propensity score. However, a limitation to 
matching is the reduction in sample size that arises from regarding unmatched subjects. 
In our study, an appropriate match could not be identified for 32 % of patients with 
statin treatment after propensity score-matching. Despite this reduction in sample size, 
the significance of statin pretreatment for preventing CI-AKI was consistent in this 
analysis. Second, the collection of creatinine following PCI was constituted 
retrospectively, and it was difficult to obtain 48- or 72-hour measurement of serum 
creatinine for all patients, thereby leading to the use of an alternative solution by 1-week 
measurement in 25% of the whole patients. However, we observed a similar relation in 
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patients who had both 48- or72 –hour and 1-week measurement of serum creatinine, 
and thus our overall findings are likely extant. Third, there was a lack of precise 
information on statin dosing and noncompliance, and safety data was insufficient during 
the follow-up period. Forth, serum level of creatinine, especially in the elderly and 
female populations, who have low muscle mass, is an inexact measure of renal function. 
Fifth, the prevalence of CAD and the cholesterol level of the Japanese population are 
different from that of Western populations [26]. Japanese patients are more susceptible 
to statin treatment than are Westerners [27]. Other limitations included the lack of data 
regarding potential other nephrotoxic agents, such as non-steroidal anti-inflammatory 
drugs, in the present study. Despite these study limitations, we found that statin 
pretreatment was associated with a significant decrease in CI-AKI development in CAD 
patients who underwent PCI. 
 
6. Conclusions 
Our observational cohort analysis showed that statin pretreatment was associated 
with a significant decrease in the incidence of CI-AKI in CAD patients undergoing PCI. 
These results could not be incorporated to the subgroup of very high value of Mehran 
risk score, because of underpowered detecting significance of CI-AKI prevention. A 
large-scale, well-designed, multicenter randomized controlled trial would be necessary 
to address the effects of statin for preventing CI-AKI, as well as improving long-term 
clinical outcomes. 
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Figure Legends 
 
Figure 1. Study flow chart. PS = propensity score. 
 
Figure 2. Incidence of contrast-induced nephropathy and statin pretreatment stratified 
by Mehran risk score among all (A) and propensity score-matched subjects (B). CI-AKI 
= contrast-induced acute kidney injury. 
 
Figure 3. Kaplan-Meier curves showing freedom from secondary composite endpoint 
based on Mehran risk score and statin pretreatemt among all (A) and propensity 
score-matched subjects (B). MRS = Mehran risk score, PCI = percutaneous coronary 
intervention. 
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Table 1. Baseline patient characteristics 
 All patients (n=2198) PS-matched patients (n=1130) 
 
With statin 
(n=839) 
Without 
statin 
(n=1359) 
P 
value 
With statin 
(n=565) 
Without 
statin 
(n=565) 
P 
value 
Age, years 69 ± 10 70 ± 11 0.004 70 ± 9 70 ± 11 0.66 
Age ≥75 years 260 (31%) 531 (39%) <0.001 194 (34%) 211 (37%) 0.32 
Male sex 629 (75%) 1064 (78%) 0.07 440 (78%) 427 (76%) 0.40 
Hypertension 650 (78%) 887 (65%) <0.001 423 (75%) 406 (72%) 0.28 
Diabetes mellitus 392 (47%) 471 (35%) <0.001 233 (41%) 236 (42%) 0.90 
Current smoker 179 (21%) 389 (29%) <0.001 125 (22%) 111 (20%) 0.34 
Chronic kidney disease 295 (35%) 475 (35%) 0.92 190 (34%) 210 (37%) 0.24 
Family history of CVD 100 (12%) 113 (8.3%) 0.006 57 (10%) 57 (10%) 1.00 
Previous PCI 264 (32%) 184 (14%) <0.001 136 (24%) 137 (24%) 1.00 
Previous CABG 89 (11%) 49 (4%) <0.001 40 (7.1%) 41 (7.3%) 1.00 
Prior myocardial infarction 197 (24%) 136 (10%) <0.001 86 (15%) 94 (17%) 0.57 
History of heart failure 64 (7.6%) 62 (4.6%) 0.003 35 (6.2%) 36 (6.4%) 1.00 
History of stroke 81 (9.7%) 108 (7.9%) 0.17 54 (9.6%) 49 (8.7%) 0.68 
History of peripheral artery disease 37 (4.4%) 36 (2.6%) 0.025 24 (4.2%) 21 (3.7%) 0.76 
Body mass index, kg/m2 24.9 ± 3.4 24.0 ± 3.5 <0.001 24.6 ± 3.5 24.4 ± 3.3 0.26 
Acute coronary syndrome 174 (21%) 852 (63%) <0.001 160 (28%) 181 (32%) 0.20 
Acute myocardial infarction 93 (11%) 638 (47%) <0.001 87 (15%) 104 (18%) 0.20 
Culprit of LAD 376 (45%) 605 (45%) 0.89 262 (46%) 262 (46%) 1.00 
Multivessel disease 232 (28%) 453 (33%) 0.005 159 (28%) 180 (32%) 0.19 
Type B2/C 348 (42%) 608 (45%) 0.13 233 (41%) 236 (42%) 0.90 
SYNTAX score 10 [6-16] 11 [7-19] <0.001 10 [6-17.5] 10 [6-17] 0.88 
Ejection fraction, % 64 [53─69] 60 [49─66] <0.001 65 [54-69] 63 [54-68] 0.16 
Ejection fraction ≤45% 96 (11%) 207 (15%) 0.01 62 (11%) 62 (11%) 1.00 
Medications before contrast exposure       
Aspirin  572 (68%) 537 (40%) <0.001 333 (59%) 331 (59%) 0.95 
Clopidogrel 405 (48%) 320 (24%) <0.001 221 (39%) 219 (39%) 0.95 
Ticlopidine 108 (13%) 97 (7.1%) <0.001 70 (12%) 62 (11%) 0.52 
Beta-blocker 248 (30%) 231 (17%) <0.001 144 (26%) 131 (23%) 0.41 
ACEI and/or ARB 372 (44%) 389 (29%) <0.001 206 (37%) 211(37%) 0.81 
Calcium channel blocker 196 (23%) 175 (13%) <0.001 119 (21%) 105 (19%) 0.33 
Nitrate 157 (19%) 214 (16%) 0.07 104 (18%) 104 (18%) 1.00 
 
Values are mean ± SD, median [first and third quartiles] or n (%).  
ACEI indicates angiotensin converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CABG = coronary 
artery bypass grafting; CVD = cardiovascular disease; LAD = left anterior descending artery; PCI = percutaneous 
coronary intervention; and PS = propensity score. 
Table 2. Laboratory data and procedure-related variables 
 All patients (n=2198) PS-matched patients (n=1130) 
 
With statin 
(n=839) 
Without 
statin 
(n=1359) 
P 
value 
With statin 
(n=565) 
Without 
statin 
(n=565) 
P 
value 
Laboratory data       
 White blood cell count 6813 ± 2477 8248 ± 4153 <0.001 6967 ± 2731 7242 ± 4757 0.24 
 Hemoglobin, g/dl 13.6 ± 1.8 13.6 ± 1.9 0.33 13.7 ± 1.8 13.5 ± 1.9 0.07 
 Plasma glucose, mg/dl 142 ± 60 157 ± 79 <0.001 142 ± 62 148 ± 71 0.10 
 Hemoglobin A1c, % 6.3 ± 1.2 6.2 ± 1.4 0.05 6.2 ± 1.1 6.2 ± 1.3 0.89 
 Total cholesterol, mg/dl 178 ± 40 192 ± 39 <0.001 178 ± 42 189 ± 36 0.002 
 Triglyceride, mg/dl 152 ± 106 139 ± 125 0.01 147 ± 92 145 ± 104 0.74 
 HDL cholesterol, mg/dl 49.0 ± 17.7 48.1 ± 15.4 0.29 48.8 ± 19.7 48.1 ± 13.4 0.53 
 LDL cholesterol, mg/dl 104 ± 33 119 ± 33 <0.001 105 ± 33 115 ± 33 <0.001 
Blood urine nitrogen, mg/dl 16.9 ± 6.5 17.2 ± 7.5 0.40 16.9 ± 5.9 17.1 ± 8.2 0.63 
Creatinine, mg/dl 0.90 ± 0.38 0.90 ± 0.36 0.95 0.89 ± 0.27 0.91 ± 0.40 0.24 
estimated GFR, ml/min/1.73m2 60.5 ± 12.3 57.4 ± 13.6 0.08 66.6 ± 18.3 66.0 ± 19.1 0.61 
Procedure-related variables       
Contrast volume, ml 177 ± 66 180 ± 64 0.34 176 ± 65 174 ± 66 0.62 
CV/GFR ratio 2.9 ± 1.5 2.9 ± 1.6 0.57 2.8 ± 1.3 2.9 ± 1.4 0.62 
Periprocedural hydration 124 (15%) 136 (10%) 0.001 78 (14%) 71 (13%) 0.60 
Oral N-acetylcystein 16 (1.9%) 17 (1.3%) 0.22 8 (1.4%) 13 (2.3%) 0.27 
Prophylactic dialysis 2 (0.2%) 4 (0.3%) 0.81 1 (0.2%) 2 (0.4%) 0.56 
Mehran risk score 5.6 ± 3.6 6.1 ± 4.1 0.006 5.6 ± 3.7 6.0 ± 3.7 0.07 
 
Values are mean ± SD or n (%). 
CV/GFR indicates contrast volume/estimated glomerular filtration rate; GFR = glomerular filtration rate; HDL = 
high-density lipoprotein; LDL = low-density lipoprotein; and PS = propensity score. 
 Table 3. Primary and secondary endpoints 
 All patients (n=2198) PS-matched patients (n=1130) 
 
With 
statin 
(n=839) 
Without 
statin 
(n=1341) 
P 
-value 
With 
statin 
(n=565) 
Without 
statin 
(n=565) 
P 
-value 
Primary endpoint       
 CI-AKI 33 (3.9%) 159 (11.7%) <0.001 20 (3.5%) 60 (10.6%) <0.001 
Secondary endpoints         
Death or requiring dialysis       
within 30 days 1 (0.1%) 18 (1.3%) 0.002 1 (0.2%) 4 (0.7%) 0.37 
within 180 days 10 (1.2%) 46 (3.4%) 0.002 7 (1.2%) 14 (2.5%) 0.19 
within 360 days 15 (1.8%) 63 (4.6%) <0.001 12 (2.1%) 20 (3.5%) 0.21 
Death       
within 30 days 1 (0.1%) 16 (1.2%) 0.005 1 (0.2%) 4 (0.7%) 0.37 
within 180 days 9 (1.1%) 43 (3.2%) 0.001 7 (1.2%) 13 (2.3%) 0.26 
within 360 days 14 (1.7%) 58 (4.5%) <0.001 12 (2.1%) 18 (3.2%) 0.28 
Requiring dialysis       
within 30 days 0 (0%) 2 (0.1%) 0.53 0 (0%) 0 (0%) NA 
within 180 days 1 (0.1%) 4 (0.3%) 0.65 0 (0%) 1 (0.2%) 1.00 
within 360 days 1 (0.1%) 6 (4.4%) 0.26 0 (0%) 2 (0.4%) 0.50 
 
Values are n (%).  
CI-AKI indicates contrast-induced acute kidney injury, NA = not applicable; and PS = propensity score. 
 
Table 4.  Multivariate Logistic Analysis for Primary Endpoint 
 
 All subjects PS-matched subjects 
 OR (95% CI) P-value OR (95% CI) P-value 
Statin pretreatment 0.62 (0.40-0.97) 0.036 0.31 (0.18-0.53) <0.001 
ACS 1.94 (1.15-3.27) 0.013 3.63 (2.26-5.85) <0.001 
EF ≤ 45% 1.97 (1.36-2.85) <0.001 2.05 (1.11-3.77) 0.021 
MRS, per increase 1.10 (1.06-1.14) <0.001   
 
ACS indicates acute coronary syndrome; CI = confidence interval; EF = ejection fraction; MRS = Mehran risk score; OR = odds ratio; and PS = propensity score. 
 
Covariates included age, male sex, statin pretreatment, acute coronary syndrome, ejection fraction ≤45%, multivessel disease, and Mehran risk score. When all subjects were 
analyzed, propensity score was also included into the model. 
 
